Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase III, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator?s Choice in Participants with Chemotherapy-na�ve Metastatic Castration-resistant Prostate Cancer
Study Type: Treatment
Phase: III
NCTID: NCT07213674
Principal Investigator:
Haoran Li
AcTFirst: A phase III, open-label, multi-center, randomized study comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration resistant prostate cancer
Study Type: Treatment
Phase: III
NCTID: NCT06855277
Principal Investigator:
Xinglei Shen
A Phase III, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA IT PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection
Study Type: Diagnostic
Phase: III
NCTID: NCT06235151
Principal Investigator:
William Parker
Phase 2 randomized Total Eradication of metastatic lesions following definitive Radiation to the Prostate in de novo oligometaStatic prostate cancer TERPS trial
Study Type: Treatment
Phase: II
NCTID: NCT05223803
Principal Investigator:
Xinglei Shen
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer
Study Type: Treatment
Phase: III
NCTID: NCT06274047
Principal Investigator:
Xinglei Shen
HoLEP prior to Radiation Therapy for Patients with LUTS/Retention and Concurrent Prostate Cancer
Study Type: Supportive Care
Phase: N/A
NCTID: NCT03802851
Principal Investigator:
Bristol Whiles
A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study ICON study number: 0798/0661
Study Type: Treatment
Phase: II
NCTID: NCT02960022
Principal Investigator:
Rahul Parikh
Quantifying Optimal Relugolix Duration with Radiation in High Risk Prostate Cancer QURE-PC
Study Type: Treatment
Phase: II
NCTID: NCT06129851
Principal Investigator:
Xinglei Shen
An Open-Label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy of AB-3028 in Patients with Castration Resistant Prostate Cancer CRPC
Study Type: Treatment
Phase: I/II
NCTID: NCT07285694
Principal Investigator:
Saqib Abbasi
PSMAcTION: A phase II/III, open-label, international, multicenter, randomized study of AAA817 versus standard of care in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu-PSMA targeted therapy.
Study Type: Treatment
Phase: II/III
NCTID: NCT06780670
Principal Investigator:
Xinglei Shen